Hal Landy, MD

Chief Medical Officer, Valerion

Dr. Landy is a board certified Pediatric Endocrinologist with 30 years of clinical research experience in academics and industry, primarily in rare orphan diseases.  Educated at Harvard College (AB ’72) and Columbia University (MD ’81), he trained at Massachusetts General Hospital and at Children’s Hospital, Boston and was on staff at Children’s Hospital and Harvard Medical School until 1996.  In 1992, he joined Serono Laboratories (Norwell, MA and Geneva, Switzerland) where he worked on numerous successful regulatory submissions in growth-related disorders, AIDS wasting and short bowel syndrome. He subsequently moved to Genzyme (Cambridge, MA), where he was VP, Clinical Research and assisted in the registration of Aldurazyme for MPS-1 and Myozyme for Pompe Disease.  In 2007, Dr. Landy joined Enobia Pharma (Cambridge, MA) as Chief Medical Officer, where he led its clinical program in hypophosphatasia, a rare and devastating disorder of skeletal mineralization, until its acquisition by Alexion in 2012 for over $1 billion.  Subsequently, Dr. Landy served as a consultant to Lotus Tissue Repair where he helped design clinical and pre-clinical development strategies for human recombinant collagen 7 for the treatment of dystrophic epidermolysis bullosa until its acquisition by Shire in 2013 for over $300 million.  Dr. Landy currently consults for several biotech companies and venture funds in Boston, New York, Washington DC, California and Europe and is consulting Chief Medical Officer for Valerion Therapeutics.  He has authored or co-authored over 20 peer-reviewed articles and chapters.